



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 8 September 2015

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date**

Important notices

- Findings of Research Misconduct ([NOT-OD-15-148](#)); ([NOT-OD-15-149](#))
- Notice Announcing FAQ Page and Pre-Application Webinar for RFA-OD-15-005 "Chemistry, Toxicology, and Addiction Research on Waterpipe Tobacco (R01)" ([NOT-OD-15-150](#))
- Notice Announcing FAQ Page and Pre-Application Webinar for RFA-OD-15-006 "Abuse Liability Associated with Reduced Nicotine Content Tobacco Products (R01)" ([NOT-OD-15-151](#))
- Notice of Technical Assistance Webinar for RFA-MD-15-012 Behavioral Interventions to Prevent HIV in Diverse Adolescent Men Who Have Sex with Men (U01)" ([NOT-MD-15-019](#))
- Notice of Pre-application Informational Webinar for RFA-NS-16-002 "NINDS Morris K. Udall Centers of Excellence in Parkinson's Disease Research Program (P50)"([NOT-NS-15-040](#))

1. Title: **Advanced Clinical Trials to test Artificial Pancreas Device Systems in Type 1 Diabetes**

Letter of Intent due date: Typically one month before the due date **Hyperlink:** ([RFA-DK-16-008](#)) **Type:** UC4

Application Due Date: March 9, 2016, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Internal Submission will be 2 days before the application due date above.

Purpose: This FOA will support the conduct of advanced clinical trials designed to test the outpatient clinical safety and efficacy of artificial pancreas (AP) device systems in type 1 diabetes with the objective of improving glycemic control, reducing acute complications and improving quality of life. These trials should generate data able to satisfy safety and efficacy requirements by regulatory agencies regarding the clinical testing of AP device systems.

Budget: The application budget is limited to a maximum of \$16,000,000 direct costs for the entire project period excluding subcontracts F&A, but budgets are expected to vary depending on the actual needs of the proposed project. The maximum project period is 5 years.

2. Title: **Sickle Cell Disease in Sub-Saharan Africa: Collaborative Consortium**

Letter of Intent due date: Typically one month before the due date **Hyperlink:** ([RFA-HL-17-006](#)) **Type:** U24

Application Due Date: February 26, 2016, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) by 8:00 PM Eastern Time on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to develop a Sickle Cell Disease (SCD) in Sub-Saharan Africa (SSA) Collaborative Consortium. The Collaborative Consortium will be responsible for developing an infrastructure upon which a future SCD in SSA Research Network can be built. This Collaborative Consortium will be comprised of a Consortium Hub (applicant institution) and at least two Collaborating Sites located in sub-Saharan African countries separate from that of the applicant institution. This program is intended to establish an SCD resource that can be shared across the collaborative consortium to enhance future research endeavors. Applications that propose a feasible plan for developing a sickle hemoglobinopathy database that can facilitate patient tracking and serve as a backbone for future SCD in SSA Research Network operations are of high programmatic interest. This FOA particularly seeks applications that propose to identify database elements and plans for harmonization of SCD phenotype definitions and ontologies and integration of Collaborative Consortium activities with those of the DCC, NHLBI, Steering Committee, Observational Study Monitoring Board, and existing training programs. Applications that describe approaches to the development of regionally appropriate standards of SCD care as well as to the organization of research and clinical skill development activities are strongly encouraged. This FOA also intends to support applications that include planned approaches to establish future SCD cohort studies, implementation of preventive/therapeutic practices, and the inclusion of new sub-Saharan African Sites to constitute the future SCD in SSA Research Network. The Collaborative Consortium will be expected to work closely with an associated Data Coordinating Center (DCC) that will be supported by a separate FOA ([RFA-HL-17-007](#)).

Budget: Application budgets may not exceed direct costs of \$590,000 in FY2017, direct costs of \$480,000 in FY2018, direct costs of \$480,000 in FY2019, and direct costs of \$640,000 in FY2020. The maximum project period is 4 years

3. Title: Sickle Cell Disease in Sub-Saharan Africa: Data Coordinating Center

Letter of Intent due date: Typically one month before the due date **Hyperlink:** [\(RFA-HL-17-007\)](#) **Type:** U24
Application Due Date: February 26, 2016, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) by 8:00 PM Eastern Time on the application due date. Internal Submission will be 2 days before the application due date above.
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to develop a Sickle Cell Disease (SCD) in Sub-Saharan Africa (SSA) Data Coordinating Center (DCC) that will support the activities of the SCD in SSA Collaborative Consortium (RFA-HL-17-006). The Collaborative Consortium comprised of a Consortium Hub and at least two additional Collaborating Sites will be responsible for developing the infrastructure for a future SCD in SSA Research Network. Applications that propose a feasible plan to provide overall project coordination, administration, data management, and biostatistical support, are of high programmatic interest. This FOA particularly seeks applications that plan for effective integration of DCC activities with those of the Collaborative Consortium, NHLBI, and review/monitoring bodies.
Budget: Application budgets may not exceed direct costs of \$790,000 in FY2017, direct costs of \$900,000 in FY2018, direct costs of \$900,000 in FY2019, and direct costs of \$740,000 in FY2020. The maximum project period is 4 years.

4. Title: Limited Competition: Multi-scale Molecular Profiling of Brains from Psychiatric Cohorts (Collaborative)

Letter of Intent due date: Typically one month before the due date **Hyperlink:** [\(RFA-MH-16-230\)](#) **Type:** RO1
Application Due Date: November 3, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) by the application due date. Internal Submission will be 2 days before the application due date above.
Purpose: The purpose of this limited competition Funding Opportunity Announcement (FOA) and the companion FOA is to seek applications to explore and establish a comprehensive landscape of multi-modal molecular alterations across brain regions, leveraging an existing human brain collection that includes the brains of patients with psychiatric disorders with the goal of developing molecular models of those disorders. This limited competition is open to the [Common Mind Consortium](#) and the [PsychENCODE Consortium](#) investigators who have access to existing large, high quality, and phenotypically well-characterized brain collections. This FOA should be used when two or more collaborating sites are essential to complete the proposed research. It is required that the Research Strategy be identical across the set of linked collaborative R01 applications, with the exception of a short section describing specific function of each application, under a heading "Elements Unique to this Site." For a linked set of collaborative R01 applications, each application must have its own Program Director/Principal Investigator (PD/PI) and the collaboration across the linked applications must include a mechanism for cross-site coordination, involving data sharing as appropriate, quality control, database management, statistical analysis, and reporting.
Budget: NIMH intends to commit \$3 million in FY2016 to support 6 awards across this FOA and its companion FOA. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this FOA may not exceed 4 years.

5. Title: Limited Competition: Multi-scale Molecular Profiling of Brains from Psychiatric Cohorts

Letter of Intent due date: Typically one month before the due date **Hyperlink:** [\(RFA-MH-16-235\)](#) **Type:** RO1
Application Due Date: November 3, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) by the application due date. Internal Submission will be 2 days before the application due date above.
Purpose: The purpose of this limited competition Funding Opportunity Announcement (FOA) and the companion FOA is to seek applications to explore and establish a comprehensive landscape of multi-modal molecular alterations across brain regions, leveraging existing human brain collections that include the brains of patients with psychiatric disorders, with the goal of developing molecular models of those disorders. This limited competition is open to the [Common Mind Consortium](#) and the [PsychENCODE Consortium](#) investigators who have access to existing large, high quality, and phenotypically well-characterized brain collections.
Budget: NIMH intends to commit \$3 million in FY2016 to support 6 awards across this FOA and its companion. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this FOA may not exceed 4 years.

6. Title: NCI Exploratory/Developmental Research Grant Program (NCI Omnibus)

Letter of Intent due date: Typically one month before the due date **Hyperlink:** [\(PAR-15-340\)](#) **Type:** R21
Application Due Date: November 10, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) by the application due date. Internal Submission will be 2 days before the application due date above.
Purpose: The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).
Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the 2-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

UC4 – NIH Research Project Cooperative Agreement: To support multi-year funded cooperative agreement research with high impact ideas that may lay the foundation for new fields of investigation; accelerate breakthroughs; stimulate early and applied research on cutting-edge technologies; foster new approaches to improve the interactions among multi- and interdisciplinary research teams; or, advance the research enterprise in a way that could stimulate future growth and investments and advance public health and health care delivery. This activity code could support either a specific research question or propose the creation of a unique infrastructure/resource designed to accelerate scientific progress in the future.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete [Glossary and acronym list of NIH Terms](#)